# A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Study · id `cardio:ct-nct04951219` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04951219](<https://clinicaltrials.gov/study/NCT04951219>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04951219

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 810 participants.

## Technical summary

Registry record NCT04951219. Randomized; triple masking; primary purpose treatment. Start 2021-07-09 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 810 participants (enrolled count; ClinicalTrials.gov record NCT04951219, source copy `cardio:ctgov-nct04951219-2026-05-27`, retrieved 2026-10-31)
- Started: 2021-07-09 (actual) (ClinicalTrials.gov record NCT04951219, source copy `cardio:ctgov-nct04951219-2026-05-27`, retrieved 2026-10-31)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT04951219, source copy `cardio:ctgov-nct04951219-2026-05-27`, retrieved 2026-10-31)
- Completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT04951219, source copy `cardio:ctgov-nct04951219-2026-05-27`, retrieved 2026-10-31)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT04951219, source copy `cardio:ctgov-nct04951219-2026-05-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04951219-2026-05-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
- Condition: Non-Alcoholic Fatty Liver Disease
- Intervention (Drug): Resmetirom
- Lead sponsor: Madrigal Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 5d32474795859dbdea3398eab3d1801d8c69f2fc27c7f6f835b17505b58ba4c5
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
